Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.
EP. 1: Selecting Frontline Therapy for Metastatic Urothelial Carcinoma
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
EP. 2: Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance Therapy
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
EP. 3: Frontline Immunotherapy for Metastatic Urothelial Carcinoma
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
EP. 4: Metastatic Urothelial Carcinoma: Experience With Maintenance Avelumab
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
EP. 5: When to Use Maintenance Therapy in Metastatic Urothelial Carcinoma
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
EP. 6: Metastatic Urothelial Carcinoma: Discussing Maintenance Therapy With Patients
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
EP. 7: Metastatic Urothelial Carcinoma: Does FGFR Status Impact Use of Maintenance Avelumab?
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
EP. 8: mUC: Duration of Maintenance Avelumab and Treatment at Progression
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
EP. 9: Selecting Second-Line Therapy for Metastatic Urothelial Carcinoma
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
EP. 10: Future Treatment Landscape of Metastatic Urothelial Carcinoma
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
EP. 11: Recap: Selecting Frontline Therapy for Metastatic Urothelial Carcinoma
2 Clarke Drive Cranbury, NJ 08512